Avidity Biosciences Inc

Insider sell‑off at Avidity Biosciences shows a routine post‑Novartis merger cleanup—no decline in confidence, but a chance for integrated growth and pipeline acceleration.

Insider sell‑to‑cover at Avidity Biosciences shows execs stay long‑term on the sidelines while the company pursues antibody‑oligonucleotide breakthroughs—read why this matters for investors.